Janet Dorling

Janet Dorling has been a member of the Board of Directors since April 2021. Ms. Dorling has been the Senior Vice President, Global Commercial Product Strategy at Gilead Sciences Inc. since May 2020. She was the Chief Commercial Officer at CymaBay Therapeutics, Inc. from August 2019 to December 2019 and the Chief Commercial Officer at Achaogen from 2017 to 2019. Previously she served as Vice President, Breast Cancer Franchise, Global Product Strategy from 2015 to 2017 at Roche, and from 2007 through 2015 served in various marketing and commercial roles at Genentech. Ms. Dorling received an M.S. from Duke University and an M.B.A. from the University of California, Berkeley.